Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Exemestane in HR+ Breast Cancer
NCT00615524Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Apr 2008
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in breast cancer, sponsored by GSK. Planned start Apr 2008; status: withdrawn.
02
Drugs
pazopanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00615524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615524.